日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Dual Lineage Tracing Identifies Cellular Mechanisms Underlying Radiation-Associated Changes in Atherosclerotic Lesion Composition

双谱系追踪揭示了辐射相关动脉粥样硬化病变成分变化的细胞机制

Deaton, Rebecca A; Raihan, Tajbir; Milosek, Victoria M; Allaham, Fatema; Krinsky, Alexandra L; Shankman, Laura S; Alencar, Gabriel F; Salamon, Anita; Moradinasab, Nazanin; Banerjee, Subhashis; Owens, Gary K

Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials

Deucravacitinib治疗中重度斑块状银屑病长达3年的安全性和有效性:一项随机临床试验的开放标签扩展研究

Armstrong, April W; Lebwohl, Mark; Warren, Richard B; Sofen, Howard; Imafuku, Shinichi; Ohtsuki, Mamitaro; Spelman, Lynda; Passeron, Thierry; Papp, Kim A; Kisa, Renata M; Vaile, John; Berger, Victoria; Vritzali, Eleni; Hoyt, Kim; Colombo, Matthew J; Scotto, Julie; Banerjee, Subhashis; Strober, Bruce; Thaçi, Diamant; Blauvelt, Andrew

Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials

Deucravacitinib治疗斑块状银屑病:POETYK PSO-1、PSO-2 和长期扩展试验的3期安全性和有效性结果

Armstrong, April W; Lebwohl, Mark; Warren, Richard B; Sofen, Howard; Morita, Akimichi; Paul, Carle; Papp, Kim A; Colombo, Matthew J; Scotto, Julie; Vaile, John; Zhuo, Joe; Vritzali, Eleni; Berger, Victoria; Schroeder, Georgene; Banerjee, Subhashis; Thaçi, Diamant; Strober, Bruce

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial

Deucravacitinib(一种选择性 TYK2 抑制剂)在银屑病关节炎中的应用:一项 II 期试验显示达到最小疾病活动度指标

Kavanaugh, Arthur; Coates, Laura C; Mease, Philip J; Nowak, Miroslawa; Hippeli, Lauren; Lehman, Thomas; Banerjee, Subhashis; Merola, Joseph F

Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

更正:Deucravacitinib改善中重度银屑病患者的患者报告结局:来自3期随机POETYK PSO-1和PSO-2试验的结果

Armstrong, April W; Augustin, Matthias; Beaumont, Jennifer L; Pham, Tan P; Hudgens, Stacie; Gordon, Kenneth B; Zhuo, Joe; Becker, Brandon; Zhong, Yichen; Kisa, Renata M; Banerjee, Subhashis; Papp, Kim A

Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study

系统性红斑狼疮新型治疗反应测量指标(TRM-SLE)的纳入领域:一项改良德尔菲研究的结果

Connelly, Kathryn; Koelmeyer, Rachel; Ayton, Darshini; May, John; Gregory, Kate; Eades, Laura E; Barallon, Raychel; Kandane-Rathnayake, Rangi; Golder, Vera; Anzum, Afia; Mydin, Maisarah; Akther, Munni; Friedman, Alan; Askanase, Anca D; Aranow, Cynthia; Vital, Edward; Pons-Estel, Guillermo; Brunner, Hermine; Kalunian, Kenneth; Dantata, Khadija; Arnaud, Laurent; Burke, Laurie; Simon, Lee S; Zuraw, Qing; Garces, Sandra; Werth, Victoria P; Sun, Ying B; Tanaka, Yoshiya; Lahoud, Youmna; Cornet, Alain; Sorrentino, Alessandro; Rahman, Anisur; Stevens, Anna; Barbey, Catherine; Dey, Ida Dzifa; Karis, Elaine; Bonfá, Eloisa; Noss, Erika; Smith, Eve M D; Stojan, George; Andersen, Jeanette; Merola, Joseph F; Ross Terres, Jorge A; Buie, Joy; Maller, Justine; Mosca, Marta; Hojnik, Maja; Dall'Era, Maria; Furie, Richard A; van Vollenhoven, Ronald F; Banerjee, Subhashis; Morand, Eric

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

Deucravacitinib 是一种口服、选择性、变构酪氨酸激酶 2 抑制剂,用于治疗活动性系统性红斑狼疮 (SLE) 患者:一项 II 期随机试验中患者报告结局的疗效

Mosca, Marta; Arnaud, Laurent; Askanase, Anca; Hobar, Coburn; Becker, Brandon; Singhal, Shalabh; Banerjee, Subhashis; Pomponi, Samantha; Choi, Jiyoon; Strand, Vibeke

Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis

在一项 II 期银屑病关节炎研究中,根据基线 DMARD 使用情况评估选择性变构 TYK2 抑制剂 Deucravacitinib 的疗效和安全性:一项事后分析

Deodhar, Atul; Nowak, Miroslawa; Ye, June Y; Lehman, Tom; Banerjee, Subhashis; Mease, Philip J

Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials

Deucravacitinib治疗斑块状银屑病:POETYK PSO-1、PSO-4和LTE 3期试验中日本患者3年安全性和有效性评估

Morita, Akimichi; Imafuku, Shinichi; Tada, Yayoi; Okubo, Yukari; Habiro, Katsuyoshi; Tsuritani, Katsuki; Banerjee, Subhashis; Hoyt, Kim; Kisa, Renata M; Ohtsuki, Mamitaro

Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study

地克拉伐替尼治疗日本斑块型、泛发性脓疱型或红皮病型银屑病患者:POETYK PSO-4 研究中的患者报告结局

Tada, Yayoi; Armstrong, April W; Imafuku, Shinichi; Okubo, Yukari; Morita, Akimichi; Zhong, Yichen; Zhuo, Joe; Becker, Brandon; Napoli, Andrew; Banerjee, Subhashis; Ohtsuki, Mamitaro